These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 33073179)

  • 1. A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.
    Diniz MA; Kim S; Tighiouart M
    Stats (Basel); 2020 Sep; 3(3):221-238. PubMed ID: 33073179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.
    Diniz MA; Quanlin-Li ; Tighiouart M
    J Biom Biostat; 2017; 8(6):. PubMed ID: 29552377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.
    Diniz MA; Kim S; Tighiouart M
    J Probab Stat; 2018; 2018():. PubMed ID: 30906326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.
    Tighiouart M; Li Q; Piantadosi S; Rogatko A
    Am J Biostat; 2016; 6(1):1-11. PubMed ID: 28706582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.
    Tighiouart M; Li Q; Rogatko A
    Stat Med; 2017 Jan; 36(2):280-290. PubMed ID: 27060889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.
    Ananthakrishnan R; Green S; Chang M; Doros G; Massaro J; LaValley M
    Contemp Clin Trials Commun; 2017 Mar; 5():34-48. PubMed ID: 29740620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
    Tighiouart M; Piantadosi S; Rogatko A
    Stat Med; 2014 Sep; 33(22):3815-29. PubMed ID: 24825779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.
    Tighiouart M; Cook-Wiens G; Rogatko A
    J Biopharm Stat; 2018; 28(3):562-574. PubMed ID: 28858566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.
    Chen Z; Tighiouart M; Kowalski J
    Contemp Clin Trials; 2012 Sep; 33(5):949-58. PubMed ID: 22561391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure driven dose escalation design with overdose control: Concept and first real life experience in an oncology phase I trial.
    Micallef S; Sostelly A; Zhu J; Baverel PG; Mercier F
    Contemp Clin Trials Commun; 2022 Apr; 26():100901. PubMed ID: 35198796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
    Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
    Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
    Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
    Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.
    Jimenez JL; Tighiouart M; Gasparini M
    Biom J; 2019 Mar; 61(2):319-332. PubMed ID: 29808507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporating lower grade toxicity information into dose finding designs.
    Iasonos A; Zohar S; O'Quigley J
    Clin Trials; 2011 Aug; 8(4):370-9. PubMed ID: 21835856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.
    Ji L; Lewinger JP; Krailo M; Groshen S; Conti DV; Asgharzadeh S; Sposto R
    Pharm Stat; 2019 Nov; 18(6):659-670. PubMed ID: 31237419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.
    Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
    Stat Med; 2011 Jul; 30(17):2070-80. PubMed ID: 21344472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?
    Tighiouart M; Jiménez JL; Diniz MA; Rogatko A
    Braz J Biom; 2022 Dec; 40(4):453-468. PubMed ID: 38357386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.
    Zhao D; Zhu J; Wang L
    Contemp Clin Trials; 2021 Mar; 102():106265. PubMed ID: 33418097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.